

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Prescient Therapeutics Limited
ABN: 56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Gavin Shepherd
Date of last notice	3 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	GavnCath Pty Ltd as trustee for the Shepherd Investment Trust (Dr Shepherd is a beneficiary of the trust fund for which the company is the trustee). Gavin James Shepherd & Catherine Jane Shepherd as trustee for the TPJ Superannuation Fund (Dr Shepherd is a beneficiary of the superannuation fund).
Date of change	11 December 2024
No. of securities held prior to change	Indirect <u>GavnCath Pty Ltd as trustee for the Shepherd Investment Trust</u> 6,385,908 Fully Paid Ordinary Shares <u>Gavin James Shepherd & Catherine Jane Shepherd as trustee for the TPJ Superannuation Fund</u> 10,000,000 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Unlisted Options exercisable at \$0.0621, expiring 11 December 2028
Number acquired	1,415,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (see below)
No. of securities held after change	Indirect <u>GavnCath Pty Ltd as trustee for the Shepherd Investment Trust</u> 6,385,908 Fully Paid Ordinary Shares 1,415,000 Unlisted Options exercisable at \$0.0621, expiring 11 December 2028 <u>Gavin James Shepherd & Catherine Jane Shepherd as trustee for the TPJ Superannuation Fund</u> 10,000,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of 1,415,000 options pursuant to Resolution 4 as approved at Prescient Therapeutics Limited's 2024 Annual General Meeting on 14 November 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.